Tamoxifen is an anti-oestrogen which is currently being assessed as a prophylactic for women at high nrsk of breast cancer. Taxoxifen has also been shown to reverse multidrug resistance in P-glycoprotein (P-gp)-expressing cells, although the mechanisim of action is unknown. In this study we demonstrate that tamoxifen interacts directly with P-gp. Plasma membranes from P-gp-expressing cells bound [3HJtamoxifen in a specific and saturable fashion. A 180 kDa membrane protein in these membranes, labelled by the affinity analogue tamoxifen aziridine and azidopine, was shown to be P-gp. Tamoxifen reduced the binding of vinblastine and azidopine to P-gp, and tamoxifen increased [3H]vinblastine accumulation in P-gp-expressing cells to levels approaching those in non-P-gp-expressing cells. However, the cellular accumulation of [3Hltamoxifen itself was not influenced by the presence of P-gp. Thus, tamoxifen appears to reverse multidrug resistance by binding to P-gp and inhibiting the transport of cytotoxic drugs. but does not itself appear to be transported by the protein.
Tamoxifen is an anti-oestrogen which displays tumoristatic properties (Lerner and Jordan, 1990) . The use of tamoxifen in the clinic has progressed from palliation in advanced breast cancer (Jordan, 1990 (Jordan, , 1992 Lerner and Jordan, 1990) to efficacious treatment of all stages of oestrogen receptorpositive breast cancer. Furthermore, tamoxifen is currently being assessed as a prophylactic agent for women at high risk of developing breast cancer (Jordan, 1990) . Tamoxifen acts by binding to the cytosolic oestrogen receptor (Katzenellenbogen et al., 1983; Berthois et al., 1986) and inhibiting the binding of oestrogens (Jordan and Prestwich, 1977; Jordan and Naylor, 1979) . Tamoxifen is tolerated to high doses and has few reported side-effects owing to its high target specificity (Jordan. 1992) .
Tamoxifen has also been demonstrated to reverse the drug resistance phenotype of several P-glycoprotein (P-gp)-expressing cell lines (Ramu et al., 1984; DeGregorio et al.. 1989 ; Kirk et al., 1993a,b) . However, it is not known whether this is an indirect effect or the result of the direct interaction of tamoxifen with P-gp. P-gp is frequently associated with the phenomenon of multidrug resistance (MDR) (Kartner et al., 1983) , acting as an ATP-dependent, drug efflux pump to reduce the intracellular accumulation of antineoplastic drugs (Inaba et al., 1979; Cornwell et al.. 1986a ; for reviews see also Riordan and Ling 1985; Honio et al., 1988; Gottesman and Pastan, 1993) . A number of compounds are known to antagonise the drug efflux activity of P-gp, such as verapamil and other calcium channel blockers, immunosuppressants (e.g. cyclosporin A), antiarrhythmics and antihistamines (for review see Gottesman and Pastan, 1993) . Many of these compounds bind to P-gp and are believed to reverse drug resistance by competing with drug binding to and/or drug transport (Wigler and Patterson, 1993) . Thus, it seemed possible that tamoxifen might also interact directly with P-gp. In this study we demonstrate that tamoxifen does indeed bind to P-gp and inhibits the transport of cytotoxic drugs, although it does not appear to be a substrate for transport. This identifies a second target for tamoxifen in certain tissues and has implications for the therapeutic use of tamoxifen.
Materia and methods

Chemicals
[3HjVinblastine sulphate (11 Ci mmol-'), [3HJazidopine (52 Ci mmol (Cornwell et al., 1986b The reactions were stopped by the addition of 2 ml of icecold labelling buffer and membranes were pelleted by centrifugation at 120 000g in a Beckman TL-100 ultracentrifuge for 15 min at 4'C. Pellets were solubilised in Laemmli sample buffer and proteins separated on a 6% sodium dodecylsulphate (SDS)-polyacrylamide gel The gels were treated with Amplify (Amersham, UK), dried onto filter paper, and labeLled proteins visualised by autoradiography.
Drug bindig to plasma membranes Drug binding to plasma membranes was assayed using a rapid filtration assay as previously described (Cfaghan and Riordan, 1993 For [3Hjvinblastine accumulation, labelled drug (0.6 pCi) was added to each plate together with unlabelled drug to a final vinblastine concentration of 21 nM. Tamoxifen was added as a competing agent in the concentration range 0-60 g-M. Cels were harvested and treated as above.
higher than values reported for vinblastine (Yusa and Tsuro, 1989) and azidopine (Tamai and Safa, 1991) , but similar to those reported for daunomycin and morphine (Callaghan and Riordan, 1993) .
Tamoxifen inhibits the binding of vinblastine to P-gp expressing membranes Vinblastine is a cytotoxic drug which binds to P-gp and is a transported substrate. The ability of tamoxifen to displace the specific binding of [3HJvinblastine to KBV-1 membranes is shown in Figure 2 . About 20.1 ± 0.9% of the total [3H] vinblasine added to the membranes was bound. For P-gpexpressing cells, 81 ± 2% of this binding was specific, as defined by its sensitivity to a 2000-fold excess of unlabeLled vinblastine. In contrast, no specific binding could be detected for membranes from non-P-gp-expressing KB3-1 cells (data not shown). Tamoxifen concentrations of 10 gM were sufficient to displace approximately 50% of the specific binding of vinblasutie to P-gp-containing membranes. This implies that tamoxifen and vinblastine bind to a common site in these membranes. The ability of tamoxifen to displace vinblastine binding compares favourably with that reported for verapamil and other calcium channel blockers.
Site of [3HJtamoxifen binding to KBV-1 plasma membranes
To identify the site of specific tamoxifen binding to KBV-1 membranes it was necessary to use affinity labelling techniques. Tamoxifen aziridine, an electrophilic analogue of tamoxifen, has previously been used to demonstrate the ability of tamoxifen to bind the oestrogen receptor (Katzenellenbogen et al., 1983). We therefore examined the abilities of [HLtamoxifen aziridine and pH]azidopine to label plasma membranes from P-gp-expressing and non-expressing cells (Figure 3) . [H] Azidopine has previously been demonstrated to label P-gp (Safa et al., 1987) and, thus, served as a positive control.
[H]Azidopine strongly labeLW a protein of approximately 180 kDa in membranes from P-gp-expressing cells which was absent from membranes of non-P-gp-expressing cells (Figure 3a) . Immunoppitation with the monoclonal antibody C219 showed that the 180kDa peptide was P-gp (data not shown). The 180 kDa protein present only in membranes from P-gp expressing cells was also labelled by [H1 tamoxifen aziridine. Thus, a significant proportion of the increased binding capacity of KBV-1 membranes to tamoxifen ( Figure 1) (Peters and Richards, 1977) .
Tarnoxifen inhibits the binding of other compounds to P-gp Affinity labelling techniques were used to demonstrate that tamoxifen interacts with the same binding site(s) on P-gp as vinca alkaloids on calcium channel blockers. The ability of vinblastine (0.1-100 M) and tamoxifen (1OOI1M) to displace the binding of [3HJtamoxifen aziridine to KBV-1 membranes is shown in Figure 4 . The displacement of tamoxifen aziridine from P-gp by vinblastine was dose dependent and almost complete at 100 iLM. In addition, we studied the ability of tamoxifen to displace the specific photoaffinity labelling of P-gp by [3Hjazidopine (Figure 5 high-affinity substrate for P-gp with a Kd of 1.5 1iM (Tamai and Safa, 1991 
Effects of twnoxifen on [3H]vinblastine accumulation in KB cells
Tamoxifen reverses drug resistance in P-gp-expressing cells.
As tamoxifen binds to P-gp, it seemed likely that it reverses drug resistance by inhibiting drug transport. To address this point we studied the effects of tamoxifen on the accumulation of [3Hlvinblastine (21 nM) Tanoxifen is not itself transported bk' P-gp The accumulation of [3H]tamoxifen by P-gp-expressing and non-expressing cells is shown in Figure 7 . In both cell lines there was a rapid initial accumulation of tamoxifen which plateaued by approximately 30 min. There was no significant difference in the steady-state accumulation of labelled tamoxifen between the two cell lines. This is in contrast to [3Hlvinblastine, which as reported in the preceding section, has a 6-fold lower accumulation in KBV-1 cells than in KB-1 cells. Tamoxifen is highly lipophilic, and approximately 80% of the total counts added were associated with the cells. The data above, which show that a similar proportion of [3H} tamoxifen associates with isolated plasma membranes, indicate that a significnt proportion of the tamoxifen is non-speifically bound to the cell membrane rather than being accumulated intracellularly. In plasma, tamoxifen is extensively bound to proteins which alter its distribution between cells and serum (Chaterjee and Harris, 1990 ). The addition of albumin (0-2%, w/v) to the transport medium caused a fall (30% at a concentration of 1.0%, w/v) in the amount of tamoxifen bound by both cell lines (data not shown). However, there was still no significant difference in accumulation between the two cell lines under these conditions. Thus, tamoxifen does not appear to be transported by P-gp despite its ability to bind to the protein and displace the binding of transported substrates.
Diso
Tamoxifen exerts tumoristatic effects through its interaction with the oestrogen receptor. Tamoxifen has generally been assumed to be relatively specific in its interactions with cel- Tamoxifen has been reported to reverse P-glycoproteinmediated multidrug resistance in vitro (Ramu et al., 1984; DeGregorio et al., 1989; Kirk et al., 1993a) . The mechanism by which this is achieved has not been established, although a recent study suggests an interaction between P-gp and tamoxifen in oestrogen receptor-positive MCF7' cells (Leonessa et al., 1994) . Many agents which reverse MDR bind specifically to P-gp and to compete with cytotoxic drugs for active transport (Cornwell et al., 1987; Safa et al., 1987; Ryffel et al., 1991) . We have shown that tamoxifen also interacts directly with P-gp. Furthermore, tamoxifen appears to inhibit drug transport since it dramatically increased vinblastine accumulation in P-gp-expressing cells. Thus, it appears that the reversal of multidrug resistance by tamoxifen is due to the interaction of tamoxifen with P-gp and the consequent inhibition of P-gp-dependent drug transport.
Tamoxifen was shown to displace the specific binding of azidopine and vinblastine to P-gp. This suggests that tamoxifen interacts directly with the drug binding site on P-gp. The precise nature of this site is unclear. Two regions on P-gp are labelled by azidopine (Bruggemann et al., 1989 (Bruggemann et al., , 1992 Yoshimura et al., 1989) , one in each half of the protein. However, it is believed that these two regions form a single drug binding site (Bruggeman et al., 1992) . It has, however, been suggested on the basis of binding and competition studies, that P-gp may have distinct binding sites for vinca alkaloids and azidopine (Tamai and Safa, 1991) . Verapamil is more efficacious at inhibiting binding to the vinca alkaloid site. However, the steroid hormone progesterone competes equally well with either vinca alkaloids or azidopine for binding to P-gp (Yang et al., 1989 (Kessel, 1986) . The interaction of tamoxifen with P-gp may be similar to that of the steroid hormone progesterone. Like tamoxifen, progesterone inhibits azidopine photolabelling of P-gp (Yang et al.. 1989) and vinca alkaloid binding to P-gp-containing plasma membranes (Yang et al., 1990) and increases the cellular levels of vinblastine (Yang et al.. 1989 ). yet does not appear to be a substrate for transport by P-gp (Yang et al., 1989; Saeki et al.. 1993) . Thus, there appear to be two classes of reversers of P-gp-mediated drug resistance. The first class consists of compounds which compete with cytotoxic drugs for binding and transport by P-gp. The second class of reversers, which includes tamoxifen and progesterone, compete for drug binding, thereby blocking transport of chemotherapeutic agents. but are not themselves transported.
In addition to its role in drug resistance, expression of P-gp is also associated with a cell volume-regulated chloride channel . Tamoxifen is also a high-affinity inhibitor of this chlonrde channel. although it is not known whether or not this inhibitory effect is mediated through the interaction of tamoxifen with P-gp (Zhang et al.. 1994) . The blockage of chloride channels by tamoxifen in the lens of the eye leads to opacity. suggesting a molecular mechanism by which tamoxifen might lead to visual impairment (Zhang et al.. 1994) . Together with the present finding that tamoxifen binds to P-gp. these data suggest that tamoxifen may interact with a number of functionally important targets. with consequent implications for the therapeutic use of this anti-cancer drug.
Abbreviatkoa MDR. multidrug resistance: P-gp. P-glycoprotein; FBS. fetal bovine serum: DMEM. Dulbecco's modified Eagle medium; PMSF. phenylmethylsulfonyl fluoride: EDTA. ethylenediaminetetraacetic acid.
